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Background: Low concentrations of HDAC inhibitors suppress inflammation, but HDAC inhibitors are toxic at higher
concentrations.
Results: ITF3056 specifically inhibits HDAC8 activity and reduces proinflammatory cytokine production from human blood
monocytes and in vivo but lacks cell toxicity.
Conclusion: Specific inhibition of HDAC8 reduces inflammation with low cell toxicity.
Significance: Inhibition of specific HDACs is preferred for treating inflammatory diseases, with fewer side effects.
ITF2357 (generic givinostat) is an orally active, hydroxamic-
containing histone deacetylase (HDAC) inhibitor with broad
anti-inflammatory properties, which has been used to treat chil-
dren with systemic juvenile idiopathic arthritis. ITF2357 inhib-
its both Class I and II HDACs and reduces caspase-1 activity in
human peripheral bloodmononuclear cells and the secretion of
IL-1 and other cytokines at 25–100 nM; at concentrations
>200 nM, ITF2357 is toxic in vitro. ITF3056, an analog of
ITF2357, inhibits only HDAC8 (IC50 of 285 nM). Here we com-
pared the production of IL-1, IL-1, TNF, and IL-6 by
ITF2357 with that of ITF3056 in peripheral bloodmononuclear
cells stimulated with lipopolysaccharide (LPS), heat-killedCan-
dida albicans, or anti-CD3/anti-CD28 antibodies. ITF3056
reduced LPS-induced cytokines from 100 to 1000 nM; at 1000
nM, the secretion of IL-1 was reduced by 76%, secretion of
TNFwas reduced by 88%, and secretion of IL-6was reduced by
61%.The intracellular levels of IL-1were 30% lower.Therewas
no evidence of cell toxicity at ITF3056 concentrations of 100–
1000 nM. Gene expression of TNF was markedly reduced
(80%), whereas IL-6 gene expression was 40% lower. Although
anti-CD3/28 and Candida stimulation of IL-1 and TNF was
modestly reduced, IFN production was 75% lower. Mechanis-
tically, ITF3056 reduced the secretion of processed IL-1 inde-
pendent of inhibitionof caspase-1 activity; however, synthesis of
the IL-1 precursor was reduced by 40% without significant
decrease in IL-1mRNA levels. In mice, ITF3056 reduced LPS-
induced serum TNF by 85% and reduced IL-1 by 88%. These
data suggest that specific inhibition of HDAC8 results in
reduced inflammation without cell toxicity.
DNA is tightly wrapped around nuclear histones and main-
tained in a state of deacetylation by histone deacetylases
(HDACs),2 silencing gene expression. In humans, there are 18
HDACs divided into classes based on their dependence on zinc
for enzyme activity (1). Class I (HDAC1, -2, -3, and -8) andClass
II (HDAC4, -5, -6, -7, -9, -10, and -11) are zinc-dependent
enzymes, whereas class III (sirtuins 1–7) are NAD-dependent
(2, 3). Although HDACs deacetylate the highly conserved
N-terminal lysines on nuclear histones, HDACs also target
cytosolic proteins, such as transcription factors and proteins,
that regulate cell proliferation,migration, and death (4). HDAC
inhibitors hyperacetylate signal transducers and activators of
transcription (STAT) (5) and NFB, both of which are associ-
ated with decreased inflammation (6).
Synthetic inhibitors of HDACs are orally active and well tol-
erated and have been used widely in medicine (reviewed in Ref.
7). Although synthetic HDAC inhibitors were developed to
increase pro-apoptotic genes in cancer (8), we have studied
HDAC inhibitors as anti-inflammatory agents using concentra-
tions significantly lower than those used for anti-tumor effects.
In both in vitro cellular assays as well as in animal models of
inflammatory and autoimmune diseases, low concentrations
of HDAC inhibitors reduce cytokine production and severity of
disease. ITF2357 (generic givinostat) is a hydroxamic acid-con-
taining, orally active inhibitor that is anti-inflammatory in the
low nanomolar range, either in vitro or in vivo (9–16). For
example, in mice with inducible (17) or spontaneous (6) diabe-
tes, a low dose of oral ITF2357 of 1.5 mg/kg/day protected the
insulin-producing islets as well as the incidence of clinical dia-
betes. In a Phase I trial in healthymales, oral givinostat reduced
the production of proinflammatory cytokines from whole
blood cultures (18). Children with systemic juvenile idiopathic
arthritis have been successfully treated with givinostat (19, 20).
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In addition, patients with hematopoietic bone marrow trans-
plantation have been treated with a related HDAC inhibitor
vorinostat, and a significant reduction in graft versus host dis-
ease was observed (21). Based on in vitro data (22), HDAC
inhibitors are also being tested in HIV-1 infections to decrease
the population of latently infected T-cells but also to reduce in
indolent inflammation of the disease (23–26).
Givinostat and vorinostat are pan-HDAC inhibitors in that
they inhibit Class I and Class II HDACs. In developing more
specific HDAC inhibitors, analogues of givinostat (ITF2357)
were generated. In the present study, we compared the effect on
cytokine production by an HDAC8-specific inhibitor ITF3056
with that of the pan-HDAC inhibitor ITF2357. Freshly
obtained human peripheral blood mononuclear cells (PBMCs)
were stimulated with LPS (for TLR4 responses), heat-killed
Candida albicans (for broad stimulation by TLRs and C-type
lectin receptors aswell asNOD-like receptors (27)) or anti-CD3
in combination with anti-CD28 antibodies (for T-cell responses);
the effect of the two analogues on cytokine production was
determined. In addition, circulating TNF and IL-1 were
measured in mice treated with ITF2357 or ITF3056 prior to
LPS.
EXPERIMENTAL PROCEDURES
Reagents—ITF2357 and ITF3056 were synthesized at Ital-
farmaco (Cinisello Balsamo, Italy), and purity was confirmed by
high performance liquid chromatography. ITF2357 was dis-
solved in water and kept at room temperature (11). ITF3056
was dissolved in DMSO to a concentration of 20 mM, divided
into aliquots, and stored at80 °C. Frozen aliquots of ITF3056
(20 mM in 100% DMSO) were freshly thawed and further
diluted in warm RPMI to different concentrations for experi-
ments. The concentrations used in these studies were 1000,
500, 200, 100, 50, and 25 nM. For 1000 nM ITF3056, the final
concentration of DMSO in cell culture is 0.005%. In parallel,
0.005% DMSO alone in RPMI was used as vehicle control, and
no effect was observed compared with RPMI alone. Lipopoly-
saccharide (LPS) Escherichia coli (055:B5) was purchased from
Sigma. Lactate dehydrogenase (LDH) cytotoxicity assay kit was
purchased from Biovision (Mountain View, CA). All related
antibodies for electrochemiluminescence (ECL) or ELISAwere
fromR&D Systems (Minneapolis,MN). Heat-killedC. albicans
UC820 was kindly provided by Professor Mihai Netea (Rad-
boud University Medical Centre, Nijmegen, The Netherlands).
Anti-human CD3 and anti-human CD28 antibodies were pur-
chased from eBioscience (San Diego, CA).
PBMC Cultures—The study was approved by the Colorado
Medical Institutional Review Board. Venous blood from
healthy consenting donors was drawn into lithium heparin-
containing tubes, and PBMCs were isolated using centrifuga-
tion over Ficoll-Hypaque cushions as described previously (11).
Cells were washed three times with 0.9% saline and resus-
pended in RPMI at 5 106/ml. For LPS stimulation, 0.5 106
cells were seeded per well in 96-flat bottom well plates and
cultured in a total of 200l of RPMI for 24 h, with or without 10
ng/ml LPS or increasing concentrations of the analogues. For
cultures with Candida or anti-CD3/CD28, 0.5 106 cells were
seeded per well in 96-round bottom well plates and cultured in
a total of 200 l of RPMI with 10% pooled human serum for 5
days, with or without Candida (106 colonies/ml) or 5 g/ml
anti-CD3 plus 1 g/ml anti-CD28 as stimuli (28, 29), in the
presence of increasing concentrations of the analogues. The
HDAC inhibitors were added 30 min before the stimuli. After
incubation times were completed, supernatants were collected
by centrifugation at 1000 rpm for 5 min and stored at 80 °C.
Cells remaining in the wells were lysed in 100 l of 0.5% Triton
X-100 in water and stored at80 °C for later analysis.
Cytokine Measurement—Supernatant human mature IL-1,
TNF, IL-6, IFN, and intracellular IL-1 were measured with
ECL assays (Bioveris, Gaithersburg, MD) as described previ-
ously (11, 30, 31). Supernatant and intracellular human IL-1
precursor and mouse serum TNF were measured by specific
ELISAs (R&D Systems). Total IL-1 was calculated by adding
extracellular and intracellular compartments of supernatant
and lysates for mature as well as precursor IL-1. The percent-
age of each compartment for either mature or precursor IL-1
was then determined for each concentration of HDAC
inhibitor.
Enzymatic Assay for HDAC Activity—Recombinant human
HDAC enzymes (HDAC1–10) were purchased from BPS (San
Diego, CA). HDAC11 was purchased from Enzo Life Sciences
(Farmingdale, NY). Activity of HDAC1, -2, -3, -6, -10, and -11
was assayed using the Fluor de Lys deacetylase substrate (Enzo
Life Sciences). HDAC8 activity was assayed using Fluor de Lys
Green deacetylase substrate (Enzo Life Science). N-Trifluoro-
acetyl-L-lysine was used to assay activity of HDAC 4, 5, 7, and 9.
Recombinant enzymes were preincubated with ITF2357 or
ITF3056 at 30 °C in a volume of 25 l in wells of a microtiter
plate. After a brief incubation, 25l of substrate was added, and
the fluorescent signal was generated by the addition of 50 l of
developer (Fluor de Lys Developer (Enzo Life Science) contain-
ing 2 M Trichostatin A (Sigma-Aldrich). For each assay, the
amount of enzyme, incubation times, assay buffer, and concen-
tration of the substrates were optimized. Positive control for
enzyme activity consisted of enzyme plus substrate without
ITF2357 or ITF3056. The fluorescence signal was detected
using a Victor multilabel plate reader (PerkinElmer Life
Sciences).
Caspase-1 Activity Assay—Human PBMCs from four donors
were stimulated with LPS (10 ng/ml) for 4 and 24 h. Based on
the reduction by ITF2357 and ITF3056 of LPS-induced IL-1
production and secretion, 25 nM ITF2357 and 1000 nM ITF3056
were selected as the optimal concentrations to assess effects on
caspase-1 activity. ITF2357 (25 nM) or ITF3056 (1000 nM) were
added 30min prior to LPS. After the supernatant was removed,
the cells were lysed using radioimmune precipitation assay
buffer (Sigma-Aldrich) containing a mixture of protease inhib-
itors and centrifuged at 12,000 rpm for 20 min at 4 °C. The
supernatants were assayed for protein content using the Bio-
Radmethod. Protein was processed for caspase-1 activity using
the fluorogenic substrate A2452 (Sigma-Aldrich). The fluores-
cence was reported as arbitrary fluorescence units generated by
1 g of sample/min (fluorescence/g/min). The data were
expressed as the percentage change in caspase-1 activity pres-
ent in the lysates of LPS-stimulated PBMCs incubated with
analogues, with the lysates from LPS only set as 100%.
HDAC8 Inhibitor Suppresses Cytokine Production
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Assays for Cytotoxicity—Three assays were used to compare
the cytotoxic effects of ITF2357 with those of ITF3056. LDH
release was measured in supernatants from freshly obtained
PBMCs cultured in 96-flat bottom well plates for 24 h in the
presence of LPS (10 ng/ml)without fetal calf serumas described
previously using the LDH cytotoxicity assay kit from Biovision
(Mountain View, CA) (22). The percentage of LDH release was
calculated according to the manufacturer’s instructions. In
addition, cell viability was assessed in PBMCs cultured in RPMI
supplementedwith 1% FCS in the presence of LPS (10 ng/ml) at
400,000 cells/ml in a 96-flat bottom well plate for 24 h. At the
end of incubation, cell viability was determined by the CellTiter
96 Aqueous One solution cell proliferation assay (Promega,
Madison, WI) according to the manufacturer’s instructions.
We also assessed cell viability in PBMC isolated from buffy coat
cells of human citrated blood. PBMCs isolated from buffy coats
were seeded at 500,000 cells/well (96-flat bottom well plate) in
RPMI with 10% FCS and incubated for 72 h in the presence of
increasing concentrations of ITF2357 or ITF3056 using the
CellTiter assay as described above.
Annexin V Staining for Monocyte Apoptosis—Monocytes
were isolated from fresh PBMCs by magnetic separation
(Monocyte Isolation Kit II, Miltenyi Biotec, Germany) and
resuspended in RPMI containing 10% FCS. Purified monocytes
were seeded at 250,000 cells/well and incubated in the presence
of increasing concentrations of ITF2357 or ITF3056 with LPS
(10 ng/ml). After 24 h, the cells were labeled with annexin
V-FLUOS (Roche Applied Science) and propidium iodide (PI)
following the manufacturer’s instructions. The percentages of
annexin V-positive and annexin V/PI-double-positive cells
were determined by flow cytometric analysis.
Caspase-3/7 Determinations for Monocyte Apoptosis—
Monocytes, isolated as described above, were incubated at
50,000 cells/well in 96-flat bottomwell plates in the presence of
increasing concentrations of ITF2357 or ITF3056 with LPS (10
ng/ml) for 24 h of incubation. The activity of caspase-3/7 was
then determined by the Apo-ONE homogeneous caspase-3/7
assay (Promega), and the amount of fluorescence was detected by
a fluorimetric plate reader (Victor-2, PerkinElmer Life Sciences).
Steady State mRNA Levels and Real-time PCR—To obtain
sufficient RNA for analysis of steady state mRNA levels of dif-
ferent cytokines, 3  106 cells were seeded per well in 24-well
plates and cultured in a total of 1200l of RPMI for 20 h,with or
without 10ng/ml LPS and increasing concentrations of the ana-
logues. The HDAC inhibitors were added 30 min before the
addition of LPS. After 20 h of incubation at 37 °C, the superna-
tants were collected, and cytokine levels were measured. The
cells were washed with PBS and lysed in RLT Plus lysis buffer.
Total RNA was collected with the RNeasy mini plus kit from
Qiagen (Hilden, Germany). Approximately 300–500 ng of total
RNAwas reverse-transcribed using the Superscript first-strand
synthesis system to obtain the cDNA (Invitrogen). Real-time
PCRwas then performed on a 7300 Real-time PCR systemwith
a cycle of 40 using Power SYBR Green PCR Master Mix
(Applied Biosystems). PCR using GAPDH-specific primers as
an internal control was performed for each RNA sample. The
forward primer for IL-1 real-time PCR was GCA CGA TGC
ACC TGT ACG AT, and the reverse primer was AGA CAT
CAC CAA GCT TTT TTG CT. The forward primer used for
TNF real-time PCR was CCC AGG CAG TCA GAT CAT
CTTC, and the reverse primer was AGCTGCCCCTCAGCT
TGA. The forward primer for IL-6 was GGT ACA TCC TCG
ACG GCA TCT, and the reverse primer was GTG CCT CTT
TGC TGC TTT CAC. For GAPDH, the forward primer was
TGC ACC ACC AAC TGC TTA GC, and the reverse primer
was GGC ATG GAC TGT GGT CAT GAG.
The relative ratio of the mRNA from each cytokine gene to
internal control (GAPDH) was calculated as: 1/2Ct (cytokine
gene minus the internal control gene). The -fold change of
mRNA from treated cells over the negative control (untreated
cells)was further calculated based on the relative ratio. Levels of
LPS-induced mRNA were set at 100%, and the percentage
change for each concentration of ITF2357 or ITF3056 was cal-
culated. The data are depicted as the mean percentage change
compared with LPS alone.
Animal Studies—Animal protocols were approved by the
University of Colorado Health Sciences Center Animal Care
and Use Committee. C57BL/6 mice were purchased from
Charles River (Reading, MA) and housed in the animal facility
for at least 5 days before use. For the comparison study,
ITF2357 at 10 mg/kg was administered orally as reported pre-
viously (11), and ITF3056 was injected intraperitoneally. One
hour after administration of the compounds, the animals were
treated intraperitoneally with LPS from Salmonella typhimu-
rium (Sigma-Aldrich) at a dose of 2.5 mg/kg. 90 min after the
LPS treatment, mice were sacrificed, and sera were collected
and stored at80 °C until further analysis of cytokine produc-
tions. A dose-response study of ITF3056 at 4, 8, and 16 mg/kg
was performed in mice injected intraperitoneallly with LPS
fromE. coli (055:B5) (Sigma-Aldrich) at 10mg/kg. After 4 h, the
serum was collected for cytokine levels. Another dose study of
ITF3056 at 1 and 5 mg/kg used a lower dose of LPS (2.5 mg/kg)
given intraperitoneally after ITF3056 injection. 4 h later, the mice
were sacrificed, and blood was collected. Blood was collected in
EDTA, separated into plasma for cytokine levels, or diluted in
RPMI for whole blood culture as described previously (33).
Statistical Analysis—Results are expressed as mean S.E. (n
is noted in the figure legends). Statistical significance was eval-
uated with Student’s two-tailed t test.
RESULTS
AComparison of the Effect of ITF2357 with That of Its Analog
ITF3056 on LPS-induced IL-1 Production and Secretion—To
find more selective HDAC inhibitors, analogues of ITF2357
were generated and assessed for inhibition of enzymatic activity
(34). Analog ITF3056 was highly specific for inhibition of
HDAC8, with IC50 at 285 nM with no significant inhibition of
other HDACs (Table 1). By comparison, ITF2357 primarily
inhibits Class I and II HDACs, and, as shown, ITF2357 inhibits
HDAC1 and -3, with an IC50 of 198 and 157 nM, respectively.
Fig. 1A illustrates the different compartments of mature and
precursor IL-1 produced in LPS-stimulated PBMC. We used
specific, non-cross-reacting ELISAs tomeasure themature and
precursor forms of IL-1 and calculated the percentage in each
compartment of the total. As shown in Fig. 1B, ITF2357 sup-
pressed total LPS-induced IL-1 production robustly com-
HDAC8 Inhibitor Suppresses Cytokine Production
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pared with the reduction by ITF3056. At 25, 50, and 100 nM,
ITF2357 reduced IL-1 secretionmore than 70% (Fig. 1C), con-
sistent with previous studies (11). However, at concentrations
of 200, 500, or 1000 nM, we observed greater variability in donor
responses (Fig. 1C, top). In contrast, ITF3056 exhibited a linear
reduction in IL-1 secretion from 200 to 1000 nM (Fig. 1C,
bottom).
We next compared the effect of ITF2357 and 3056 on the
level of the intracellular IL-1 precursor. Fromprevious studies
(35, 36), in freshly obtained human PBMCs, 10–15% of the
total intracellular content of the IL-1 precursor is processed
by caspase-1 and secreted during a 24-h culture of monocytes,
whereas most of the precursor remains unprocessed in the
cells. This was also observed in the present study. Although at
50 and 100 nM, ITF2357 reduced the level of the IL-1 precur-
sor by 50% (Fig. 1D, top), at 500 and 1000 nM, the reduction is
probably due to cell death (11). In contrast, there was a linear
reduction of the precursor by the analog ITF3056, which
reached statistical significance at 500 and 1000 nM (Fig. 1D,
bottom). These data indicate that ITF3056 at 500–1000 nM
concentrations reduces the synthesis of IL-1 and are consis-
tent with the reduction in LPS-induced mRNA (see Fig. 4B).
We further compared the effects of ITF2357 and ITF3056 on
the efficiency of IL-1 secretion by calculating the percentage
of secreted IL-1 over total IL-1 production (Fig. 1E).
Although ITF2357 inhibited the percentage of secreted IL-1 at
TABLE 1
Inhibition (IC50) of HDACs by ITF2357 or the analogue ITF3056
ITF hHDAC1 hHDAC2 hHDAC3 hHDAC8 hHDAC4 hHDAC5 hHDAC7 hHDAC9 hHDAC6 hHDAC10 hHDAC11
2357 198 325 157 854 1059 532 524 541 315 340 292
3056 2033 3000 3000 285 10000 10000 10000 10000 3000 3000 3000
FIGURE 1. Comparison of the effect of ITF2357with that of the analog ITF3056 on LPS-induced IL-1 production in PBMC cultures. A, diagram depicts
LPS (10 ng/ml) stimulation of PBMC cultures from nine healthy subjects. Shown is IL-1 as measured in the different compartments using specific assays for
mature IL-1 and the IL-1 precursor. B, mean S.E. dose-response of total IL-1 as a percentage change of ITF2357 (top) or ITF3056 (bottom). C, mean S.E.
percentage change of secretedmature IL-1 as measured in the supernatants. Data are derived from cultures shown in B. D, mean S.E. percentage change
of lysate containing the intracellular IL-1precursor in cultures shown in B. E, mean S.E. of the percentage of the secretedmature IL-1 specific over the total
IL-1 of data derived from B–D. F, mean S.E. of the percentage of the IL-1 precursor asmeasured in the supernatants over total IL-1. ***, p	 0.001; **, p	
0.01; *, p	 0.05, compared with LPS alone.
HDAC8 Inhibitor Suppresses Cytokine Production
JANUARY 23, 2015•VOLUME 290•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2371
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on February 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
25 and 50 nM, with increasing concentrations, there was more
IL-1 compared with LPS without ITF2357. In contrast,
ITF3056 reduced the percentage of secreted IL-1 in a linear
fashion, which reached significance at 1000 nM (p	 0.05).
We next measured the level of caspase-1 activity in the
lysates of PBMC after LPS stimulation in the presence of
ITF2357 compared with ITF3056. As shown in Fig. 2, ITF2357
reduced caspase-1 activity by50% 24 h after LPS (p
 0.002),
whereas ITF3056 showed no inhibition of caspase-1 activity
(p 
 0.19). At 4 h following LPS, both ITF2357 and ITF3056
showed no significant effect on caspase-1 activity when com-
pared with LPS alone.
From our previous study, ITF2357 at concentrations of 250
nM or higher can be injurious to PBMCs (11); thus, the percent-
age of secreted IL-1 over total IL-1 production at 500 and
1000 nM could be related to increased release of the IL-1 pre-
cursor from the disrupted cell membrane and cell death. The
amount of secreted precursor IL-1 was calculated as the per-
centage of total IL-1 production (Fig. 1F). ITF2357 at 500 and
1000 nM specifically enhanced precursor IL-1 release from the
cell but not at lower concentrations (	200 nM).
We also examined the levels of intracellular IL-1 in cell
lysates. Immunoassays for IL-1 detect both the precursor and
processed forms of the cytokine. ITF2357 reduced IL-1 levels
significantly from 25 nM (35% reduction) to 200 nM (31% reduc-
tion). However, the reductions of 80 and 90% at 500 and 1000
nM are probably due to cell death. The analog ITF3056 exhib-
ited a linear reduction, reaching statistical significance at 500
nM (24% reduction) and 1000 nM (32% reduction).
Lack of Cytotoxicity by HDAC-8 Inhibition—We used the
release of LDH to first assess the cytotoxic effects of these ana-
logues. As shown in Fig. 3A, ITF2357 resulted in the release of
LDH at 200, 500, and 1000 nM, whereas ITF3056 at these same
concentrations had no effect on LDH release. Similar findings
were observed in PBMCs isolated from either fresh blood or
buffy coat cells using a cell proliferation assay. For LPS-stimu-
lated PBMC obtained from fresh blood, 87% of cells were viable
with 123 nM ITF2357 but only 63% viable at 370 nM and only
52.5% viable at 1000 nM. In contrast, more than 93% cells were
viable even at 1000 nM ITF3056. For PBMCobtained frombuffy
coats, at 123, 370, and 1111 nM ITF2357, there were corre-
spondingly 63, 40, and 32% viable cells, whereas 87% of cells
remained viable at 1111 nM ITF3056. Because monocytes are
themajor producers of the cytokines induced by LPS, we deter-
mined annexin V staining in isolated monocytes (Fig. 3B) as
well as activation of caspase-3/7 (Fig. 3C). Consistently,
ITF3056 lacked cell toxicity even at 1000 nM, whereas ITF2357
was toxic beginning at 200 nM.
A Comparison of the Effect of ITF2357 with That of ITF3056
on LPS-induced IL-1 Steady State mRNA Levels—As shown in
Fig. 4A, at 50 nM, IL-1 mRNA was reduced by nearly 70% by
ITF2357. However, as shown above, at 500 nM, the reduction in
mRNA is due to cell injury. Although ITF3056 reduced IL-1
mRNA levels dose-dependently, the reduction did not reach
significance. Fig. 4B also shows the reduction of secreted IL-1
in the same cultures. Unlike ITF2357, the inhibitory effect of
ITF3056 on mRNA levels as well as secretion of IL-1 is linear
and without significant cell death.
Effect of ITF3056 on LPS-induced TNF Secretion and Gene
Expression Compared with ITF2357—Fig. 5A (left) depicts the
dose-response of ITF2357 inhibition of secreted TNF follow-
ing 24-h LPS stimulation. As shown, the greater reductions
were at 50 and 100 nM, but at 200, 500, and 1000 nM, increasing
levels of TNF are present, suggesting cell injury. Starting at 50
nM, there is a progressive reduction of TNF in the presence of
ITF3056 with inhibition of 75% at 500 nM and 85% at 1000 nM
(Fig. 5A, right). In a separate PBMCs culture, 20-h LPS-induced
TNFmRNA levels were also determined. There was a reduc-
tion in TNF mRNA of 85% at 50 nM ITF2357 (Fig. 5B, left).
ITF3056 also suppressed TNF gene expression starting at 100
nM and dose-dependently reduced TNFmRNA levels by 80%
at 1000 nM (Fig. 5B, right).
Effect of ITF3056 on LPS-induced IL-6 Secretion and Gene
Expression Compared with ITF2357—ITF2357 suppresses the
production of IL-6 in PBMCs stimulated with TLR agonists as
well as the combination of IL-12 plus IL-18 (11). As shown in
Fig. 6A (left), IL-6 secretion decreased to 50% at 50 nM ITF2357,
but at 100 and 200 nM, there was no reduction. The reductions
at 500 and 1000 nM (70 and 80%) are probably due to cell death.
The effect of the HDAC8 inhibitor ITF3056 is shown in Fig. 6A
(right) and reveals a linear dose response with maximal reduc-
tion of 60% at 1000 nM. In Fig. 6B (left), the levels of LPS-in-
duced IL-6 mRNA in a 20-h PBMC culture (as in Fig. 5B)
treated with ITF2357 parallel those of the protein. There is a
reduced level at 50 and 100 nM, but the reductions at higher
concentrations are related to cell death. In contrast, in PBMCs
exposed to ITF3056, the steady state levels of IL-6 mRNA
exhibit the same linear dose-response curve with a 50% reduc-
tion at 1000 nM, and the mRNA levels parallel those of the
protein (Fig. 6B, right).
The Effects of ITF Analogues 2357 and 3056 on Candida-
induced Cytokine Secretion—We next assessed the T-cell pop-
ulation employing antigen recall using heat-killed C. albicans.
There are two components of the C. albicans cell wall: an outer
layer that is composed of glycoproteins and an inner layer that
contains polysaccharides. Immune responses can be induced by
components from the outer layer of the cell wall but also by
components from the inner layer. Several classes of pattern rec-
ognition receptors have been implicated in the recognition of
the Candida pathogen-associated molecular patterns and the
FIGURE 2.Differential effects of ITF2357 and ITF3056 on caspase-1 activ-
ity.Mean S.E. of caspase-1 activity in PBMC lysates 4 h (left) and 24 h (right)
after LPS (10ng/ml). Caspase-1 activity is expressedas thepercentagechange
of the mean value of each assay with LPS set at 100% (see “Experimental
Procedures” for details). ITF2357 (25 nM) and ITF3056 (1000 nM) were added
30minbefore LPS; the concentrationswerebasedon thedata shown in Fig. 1.
n 
 4 donors; significant (p 	 0.05) or non-significant (p  0.05) p values
compared with control condition are provided above the corresponding
graph bars. ***, p	 0.001; **, p	 0.01; *, p	 0.05, compared with control.
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induction of innate host responses. These include the Toll-like
receptors (TLR2/4/9); the C-type lectin receptors, such as dec-
tin-1/2 and the macrophage mannose receptor; and the NOD-
like receptors (27, 37). In this model, there is a requirement for
activation of the monocyte and IL-1 dependence (28, 38, 39).
Both ITF2357 and ITF3056 reduced Candida-induced IL-1
and TNF secretion (Fig. 7A). IFN in the same cultures was
reduced for both ITF2357 and ITF3056 (Fig. 7B).
Suppression of Anti-CD3/28-induced IL-1 and TNF by
HDAC Inhibition—Anti-CD3 together with anti-CD28 is
widely used to trigger T cells via the T-cell receptor and CD28
co-stimulatory signal (29, 37, 40), thereby mimicking T cell
activation during antigen presentation. During a 5-day co-cul-
ture with PBMCs, T cells are activated by anti-CD3/28 and
induce production of macrophage proinflammatory cytokines,
such as IL-1 and TNF (29). As shown in Fig. 8A, ITF2357
significantly inhibited anti-CD3/28-inducedTNF secretion in
PBMCs by 75% but not IL-1 (Fig. 8A, left). The reduction by
ITF3056 of IL-1 and TNF secretion was observed at 100 nM
and higher (Fig. 8A, right). We also measured anti-CD3/28-
induced IFN in the same cultures and observed partial inhibi-
tion for ITF3056 but not ITF2357 (Fig. 8B). At 500 nM ITF2357,
there is significant cell death (see Fig. 3).
Effect of ITF3056 on Cytokine Production during Endo-
toxemia—The ability of ITF3056 to affect circulatingTNF and
IL-1 following LPS challenge was assessed. ITF3056 at 0.1, 1,
and 10 mg/kg was injected intraperitoneally into mice 1 h
before an intraperitoneal injection of LPS (2.5 mg/kg). After 90
min, themicewere sacrificed, and bloodwas collected. ITF2357
at 10 mg/kg was used as a positive control and, as expected,
reduced serum TNF by 60%. Strikingly, pretreatment of
ITF3056 starting at 0.1 mg/kg significantly reduced the circu-
lating TNF by nearly 90% (Fig. 9A). To achieve a significant
increase in serum IL-1 production, a higher dose of LPS was
injected (10 mg/kg), and blood was collected after 4 h. ITF3056
suppressed circulating IL-1 linearly, by 45% at 4 mg/kg,
70% at 8 mg/kg, and more than 80% at 16 mg/kg (Fig. 9B).
Similarly, when pretreated with lower doses of ITF3056 (1 or
5 mg/kg), there was a 22% reduction for 1 mg/kg and 40% for
5 mg/kg.
FIGURE 3. Cytotoxicity differences between ITF2357 and ITF3056. A, mean S.E. percentage change of LPS-induced LDH release with increasing concen-
trations of ITF2357 (left) or ITF3056 (right) in nine donors derived from data shown in Fig. 1. ***, p	 0.001; **, p	 0.01; *, p	 0.05, compared with LPS alone.
B, apoptosis and necrosis inmonocytes by annexin V/PI staining. Purifiedmonocytes (see “Experimental Procedures”) in RPMI were incubatedwith increasing
concentrations of ITF2357 or ITF3056 in the presence of LPS. After 24 h, the percentage of annexin V and PI-positive cells was determined. C, 24 hmean S.E.
caspase-3/7 activation in purified monocytes incubated with increasing concentrations of ITF2357 or 3056 in the presence of LPS (n
 3 donors). The data of
B and C are expressed as mean -fold increase compared with monocytes without ITF2357 or ITF3056.
FIGURE 4.Comparison of the effect of ITF2357with that of ITF3056 on LPS-induced IL-1 steady statemRNA levels. Shown is dose response of ITF2357
(A) and ITF3056 (B) in PBMC cultured in a 24-well plate with 10 ng/ml LPS for 20 h. Shown ismean S.E. percentage change of LPS-induced IL-1mRNA levels
compared with the corresponding supernatant levels of mature IL-1with increasing concentrations. n
 4 donors; ### or ***, p	 0.001; ## or **, p	 0.01; #
or *, p	 0.05, compared with LPS alone.
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In parallel, we used an assay of LPS-induced IL-1 secre-
tion from whole blood cultured from ITF3056-pretreated
mice and observed a 24 and 23% reduction for 1 and 5 mg/kg.
These data are consistent with LPS-stimulated PBMC cul-
ture (Fig. 1).
DISCUSSION
Although HDAC inhibitors have been and are still being
developed to treat cancer, their ability to reduce the production
of cytokines in vitro and disease severity in animal models of
inflammatory and autoimmune conditions (as reviewed in Ref.
9) has prompted renewed interest in compounds that target
specific HDACs. It is expected that monospecific inhibition of
HDACs will offer optimal safety and efficacy, depending on the
dominant cell type or mechanism in a particular disease (9). In
this present study, we have compared ITF2357 with the analog
ITF3056 on cytokine production as well as gene expression in
freshly obtained primary human PBMC. ITF2357 inhibits sev-
eral HDACs (both class I and class II HDACs), but ITF3056 is
unique in that it is highly specific for inhibition of HDAC8.
FIGURE 5. Comparison of the effect of ITF2357 with that of ITF3056 on LPS-induced TNF secretion and steady state mRNA levels. A, mean  S.E.
percentage change from LPS-induced TNF secreted (472 149 pg/ml, n
 15 donors) with increasing concentrations of ITF2357 (left) or ITF3056 (right). The
cells were seeded on 96-well plates with 0.5 106 PBMCs/well and stimulated with or without 10 ng/ml LPS for 24 h before the supernatant was collected for
cytokine measurement. Data are derived from nine donors shown in Fig. 1 with an additional six donors (15 total donors). B, mean S.E. percentage change
from LPS-induced TNFmRNA synthesis and the corresponding supernatant TNF with increasing concentrations of ITF2357 (left) or ITF3056 (right) (n
 4
donors). For this study, 3 106 PBMCs were seeded on a 24-well plate with or without 10 ng/ml LPS for 20 h. For all panels, ### or ***, p	 0.001; ## or **, p	
0.01; # or *, p	 0.05, compared with LPS alone.
FIGURE 6. Comparison of the effect of ITF2357 with that of ITF3056 on LPS-induced IL-6 secretion and steady state mRNA synthesis. A, mean S.E.
percentage change fromLPS-induced supernatant IL-6 (22,5698149pg/ml,n
15donors)with increasing concentrations of ITF2357 (left) or ITF3056 (right).
Data are derived from cultures shown in Fig. 5A. B, mean S.E. percentage change fromLPS-induced IL-6mRNA synthesis and the corresponding supernatant
IL-6 with increasing concentrations of ITF2357 (left) or ITF3056 (right) (n
 4 donors). Data are derived from cultures shown in Fig. 5B. For all panels, ### or ***,
p	 0.001; ## or **, p	 0.01; # or *, p	 0.05, compared with LPS alone.
HDAC8 Inhibitor Suppresses Cytokine Production
2374 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290•NUMBER 4•JANUARY 23, 2015
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on February 28, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Suppression of cytokine production by ITF3056 comparedwith
that of the pan-HDAC inhibitor ITF2357 was evaluated in
PBMCs from the same donor in the same cultures.
One important difference between ITF2357 and ITF3056 is
the lack of cell injury by ITF3056. We have reported that con-
centrations of ITF2357 of 250 nM or higher are injurious to
PBMCs, as determined by LDH release as well as annexin stain-
ing (11), and presently confirm this observation.Measurements
with annexinV staining or caspase-3/7 activation also indicated
that concentrations of ITF2357 greater than 250 nM lead to
monocyte apoptosis (Fig. 3). In marked contrast, ITF3056 was
devoid of cell injury using either assay. In fact, at 200 nM,
PBMCs exposed to ITF3056 released less LDH compare with
the LPS alone, suggesting that ITF3056 may enhance cell sur-
vival under these conditions. Therefore, the reductions in cyto-
kine production as well as gene expression by ITF3056 at 1000
nM can be assumed to be due to HDAC inhibition and inde-
pendent of cell injury.
FIGURE 7. Comparison of ITF2357with the analog ITF3056 on Candida-induced cytokines. Supernatants from PBMCwere cultured in a 96-round bottom
well plate and stimulated with heat-killed C. albicans for 5 days. A, mean  S.E. percentage change from Candida-induced IL-1 or TNF with increasing
concentrations of ITF2357 (left) or ITF3056 (right). B, mean S.E. percentage change from Candida-induced IFN with increasing concentrations of ITF2357
(left) or ITF3056 (right). n
 6 donors; ### or ***, p	 0.001; ## or **, p	 0.01; # or *, p	 0.05, compared with Candida alone.
FIGURE 8. Comparison of the effect of ITF2357 with that of ITF3056 on anti-CD3/28-induced cytokine production. Cells were cultured with the combi-
nation of 5 g/ml anti-CD3 plus 1 g/ml anti-CD28 for 5 days. A, mean  S.E. percentage change from anti-CD3/28-induced secretion of IL-1 or TNF as
measured in the supernatants with increasing concentrations of ITF2357 (left) or ITF3056 (right). B, mean S.E. percentage change from anti-CD3/28-induced
IFNwith increasing concentrations of ITF2357 (left) or ITF3056 (right). n
 5 donors; ### or ***, p	 0.001; ## or **, p	 0.01; # or *, p	 0.05, compared with
anti-CD3/28 alone.
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The other notable difference between ITF2357 and ITF3056
is the dose-response relationship. For each cytokine or cytokine
gene expression, ITF3056 consistently exhibited a linear
decrease to 1000 nM. On the other hand, ITF2357, which con-
sistently inhibited cytokines at 25, 50, and 100 nM, failed to
inhibit at 200 nM. This loss in inhibition can be observed in Figs.
1 and 5, for IL-1 and TNF, respectively. This effect of
ITF2357 is probably due to cell injury in that higher concentra-
tions increase the release of LDH (Fig. 3A) and therefore leak-
age of the IL-1 precursor from the cell. Because the intracel-
lular levels of the IL-1 precursor are markedly low at these
higher concentrations (Fig. 1D), the increase in secreted IL-1
is not due to greater caspase-1 processing but rather to the
release of the precursor itself. Indeed, we did detect increased
release of the IL-1 precursor as a percentage of the total IL-1
produced by the cells, at 500 and 1000 nM ITF2357 (Fig. 1F).
Thus, the release of the IL-1 precursor also serves as an indi-
cator of loss of membrane integrity and early cell death.
The increase in the release of the IL-1 precursor observed at
high concentrations of ITF2357 is probably not relevant to the
effective dose of ITF2357 in the treatment of systemic onset
juvenile idiopathic arthritis. The children received a daily oral
dose of 1.5 mg/kg, which results in a peak blood level less than
100 nM (18, 20). Animal studies with ITF2357 also demon-
strated optimal efficacy of oral ITF2357 in protecting mouse
islets from streptozotocin toxicity at 1.25 and 2.5 mg/kg. In
vitro, ITF2357 at 62.5 and 125 nM reduced cytokine-induced
toxicity in rat and mouse beta cells (17, 41). In the non-obese
diabeticmousemodel of Type 1 diabetes, ITF2357 added to the
drinking water prevented the spontaneous development of dia-
betes (6). The daily dose of ITF2357 in that studywas calculated
at 1 mg/kg. Therefore, the efficacy of ITF2357 is observed at
concentrations considerably less than 200 nM both in vitro and
in vivo. In contrast, ITF3056 in vitro at 1000 nM is not toxic.
Following LPS stimulation of freshly obtained human
PBMCs, activated caspase-1 cleaves the IL-1 precursor, and
the processed IL-1, together with the uncleaved precursor as
well as other contents of the secretory lysosomes, is released by
exocytosis in the absence of cell death (42). Although ITF2357
inhibits LPS-induced IL-1 release by preventing exocytosis of
IL-1-containing secretory lysosomes (16), ITF2357 does not
directly inhibit the enzymatic activity of caspase-1 (11, 16). In
the present study, we measured caspase-1 activity in the cell
lysates from ITF2357- and ITF3056-treated PBMC and found
that after 24 h, but not after 4 h, ITF2357 at 25 nM significantly
reduced LPS-induced caspase-1 activity by 50% (Fig. 2), most
likely due to a reduction in the amount of the enzyme.Although
ITF3056 at 1000 nM had no effect on caspase-1 activity in cell
lysates, the analog reduced the level of intracellular IL-1 pre-
cursor (Fig. 1D), which may partially explain the reduction in
mature IL-1 secreted into the extracellular space.
We also observed a significant inhibition of IL-1 steady
state mRNA synthesis by ITF2357 in LPS-stimulated PBMCs
after 24 h (Fig. 4A). The percentage reduction in IL-1mRNA
at 100 nM is 70%, which differs from a former study in which
ITF2357 did not affect LPS-induced IL-1 mRNA levels as
assessed by Northern blot analysis (11). In contrast, ITF3056
exhibited non-significant reductions in IL-1 mRNA levels
with only 20% at 1000 nM. Nevertheless, there was a 40% reduc-
tion in IL-1 secretion at 200 nM and 80% at 1000 nM (Figs. 1C
and 4B).
Similar to the previous study (11), we observed a reduction in
mRNA levels of TNF by ITF2357 (Fig. 5B). ITF3056 reduced
LPS-induced TNF and IL-6 mRNA synthesis in parallel to
cytokine secretion (Figs. 5B and 6B). Amarked (80%) reduction
in TNF mRNA synthesis and nearly 95% reduction in its
secretion were observed. For IL-6, mRNA levels were reduced
by 50%, and secretion of the cytokine was reduced by 70%.
ITF2357 also inhibited IL-6 mRNA synthesis (Fig. 6B, left), but
similar to its reduction in IL-6 secretion, the inhibition is
observed at the lower concentrations of 50 and 100 nM.
In addition to the LPS-induced cytokines, we also observed
significant inhibition of Candida-induced release of IL-1,
TNF, and IFN by both ITF2357 and ITF3056 (Fig. 7).
Because Candida activates glucan and mannose receptors as
well as Toll-like receptors (37), it was not surprising that we
observed similar trends in the reduction of IL-1 and TNF
induced by Candida and LPS. ITF2357 had been shown to
inhibit LPS- as well as IL-12/IL-18-induced IFN but not anti-
CD3-induced IFN (11). Here, we demonstrate that both
ITF2357 and ITF3056 reduced Candida-induced IFN but not
by anti-CD3/28 antibodies, which directly stimulate T cells
(Figs. 7B and 8B). These consistent data indicate that the Can-
dida-induced IFN is macrophage-dependent and that the
effects of ITF2357 and ITF3056 are mainly on macrophages in
the PBMC culture. Although we detected a low level of inhibi-
tion by ITF3056 on anti-CD3/28-induced IL-1 and TNF
(Fig. 8A), the effect is probably through an interaction between
FIGURE 9. Effect of ITF3056 on in vivo endotoxemia-induced cytokine production. A, mean serum TNF levels of ITF2357 (10 mg/kg)- or ITF3056-treated
mice (5mice/group) 90min after intraperitoneal injection of 2.5mg/kg LPS. B, mean S.E. percentage change of plasma IL-1 from ITF3056-treatedmice 4 h
after intraperitoneal injection of 10 mg/kg LPS compared with vehicle-treated mice (5 mice/group).
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T cells andmacrophages. In the 5-day culture of PBMCs, which
is a mixed population of monocytes and lymphocytes, there is
prolonged interaction between macrophages and T cells. For
example, IL-18 and IL-12 secreted by activated macrophages
could further activate the T cells in the co-culture to induce
IFN production (32). In fact, ITF2357 inhibits IL-18- and
IL-12-induced IFN in PBMCs, with a 50% reduction at 25 nM
(11).
We tested the in vivo effect of ITF2357 and ITF3056 on cir-
culating IL-1 and TNF after LPS challenge. Previous studies
showed that ITF2357 reduces LPS-induced circulating TNF
(11), which was confirmed in the present study. However,
ITF3056 was highly effective in reducing LPS-induced plasma
TNF levels at low doses of 0.1 mg/kg (Fig. 9A). The exact
differences between the in vitro and in vivo effects of ITF3056
are not clear. However, consistent with the in vitro study, a
linear dose-response relationship is again observed in IL-1
production in vivo (Fig. 9).
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